Ajinomoto Althea, a contract manufacturing organization providing development and manufacturing services for biotechnology and pharmaceutical companies, has appointed J. David Enloe Jr. president and CEO. Enloe will be responsible for developing strategies to support the company's continued growth.
Enloe brings over 20 years of executive management experience in biotechnology, drug development and GMP manufacturing management. Most recently, he was the head of the Viral Therapeutics Business Unit at Lonza, which provides process development, scale-up and GMP manufacturing of viral-based biologics for clients in the U.S., Europe and Asia. David was the founder and CEO of Vivante GMP Solutions, which he subsequently sold to Lonza in 2010. Previously, he was president and CEO of Introgen Therapeutics, which later became the basis for Vivante.